Yaung-Kaung Shen

发表

Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials

C. Griffiths, P. Foley, K. Gordon, 2018, JAMA dermatology.

Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double‐blinded, placebo‐ and active comparator–controlled VOYAGE 1 trial

A. Kimball, K. Papp, Y. Wasfi, 2017, Journal of the American Academy of Dermatology.

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.

K. Reich, K. Gordon, Y. Wasfi, 2015, The New England journal of medicine.

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled,

A. Gottlieb, P. Rahman, I. McInnes, 2014, Annals of the rheumatic diseases.

Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies

A. Armstrong, K. Papp, K. Reich, 2018, American Journal of Clinical Dermatology.

Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension

C. Wouters, P. Woo, E. Silverman, 2009, Annals of the rheumatic diseases.

Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study.

A. Armstrong, E. Muñoz-Elías, K. Reich, 2019, The Journal of investigative dermatology.

Amphiregulin from Basophils Ampliﬁes Basophil-Mediated Chronic Skin Inﬂammation

Honghui Zhou, Shu Li, J. Marini, 2019 .

Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS).

Baoxi Wang, M. Zheng, Michael Song, 2013, Journal of drugs in dermatology : JDD.

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

A. Gottlieb, A. Menter, A. Kavanaugh, 2009, The Lancet.

Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial

A. Gottlieb, A. Menter, A. Kavanaugh, 2010, Current medical research and opinion.

Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1

K. Papp, Chenglong Han, Y. You, 2020, The Journal of dermatological treatment.

Maintenance of clinical response and consistent safety profile with up to three years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials.

A. Kimball, A. Armstrong, K. Papp, 2019, Journal of the American Academy of Dermatology.

Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.

A. Kimball, K. Papp, A. Blauvelt, 2018, Journal of drugs in dermatology : JDD.

Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2

M. Gooderham, F. Kerdel, L. Puig, 2019, The Journal of dermatological treatment.

15280 Characterization of super responders to guselkumab treatment in moderate to severe psoriasis: Results from the VOYAGE 1 and 2 clinical trials

B. Strober, K. Reich, P. Foley, 2020 .

Consistent safety profile with up to five years of continuous treatment with guselkumab: pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis.

K. Papp, Y. You, A. Blauvelt, 2021, Journal of the American Academy of Dermatology.

Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients with Moderate-to-Severe Plaque Psoriasis.

Honghui Zhou, Shu Li, J. Marini, 2019, The Journal of investigative dermatology.

Ritchlin, C. et al. (2014) Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double

A. Gottlieb, P. Rahman, I. McInnes, 2014 .

A. Gottlieb, P. Rahman, I. McInnes, 2014, Annals of the rheumatic diseases.

28095 Long-term safety of guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials with up to 5 years of treatment

C. Griffiths, K. Papp, K. Reich, 2021 .

Anxiety and depression in patients with moderate‐to‐severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study

K. Reich, P. Foley, Chenglong Han, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study

A. Armstrong, K. Reich, P. Foley, 2020, American Journal of Clinical Dermatology.

The safety of ustekinumab treatment in patients with moderate‐to‐severe psoriasis and latent tuberculosis infection

M. Song, Y. Wasfi, Y. Shen, 2012, The British journal of dermatology.

Serious Gastrointestinal-Related Adverse Events Among Psoriasis Patients Treated With Guselkumab in VOYAGE 1 and VOYAGE 2.

M. Lebwohl, C. Griffiths, K. Reich, 2021, Journal of drugs in dermatology : JDD.

Guselkumab for the treatment of patients with moderate‐to‐severe hidradenitis suppurativa: A phase 2 randomized study

A. Kimball, K. Papp, Chenglong Han, 2023, Journal of the European Academy of Dermatology and Venereology : JEADV.

Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension

S. Visvanathan, E. Giannini, D. Lovell, 2009, Annals of the rheumatic diseases.